Portola Pharmaceuticals Appoints Two Biotechnology Industry Veterans, Laura Brege and Dr. Dennis Fenton, to Board of Director...
09 Février 2015 - 10:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced the
appointment of Laura Brege and Dennis Fenton, Ph.D., to its board
of directors. Ms. Brege serves as president and chief executive
officer of Nodality, Inc., a life sciences company focused on
innovative personalized medicine. Dr. Fenton is the owner and chief
executive officer of Fenton and Associates, a biotechnology
consulting firm.
"Laura and Dennis have directly relevant experience to help
Portola execute on the regulatory approvals and launches of our
steady stream of well-differentiated, groundbreaking products in
thrombosis, hematologic cancers and other diseases in 2016, 2017
and beyond," said Bill Lis, chief executive officer of Portola.
"They each have a strong track record of Board leadership and
operational success in manufacturing, strategic partnerships and
global commercialization. This expertise will be invaluable as we
enter this next exciting phase of our evolution to become a leading
independent biopharmaceutical company with multiple marketed
products on a global scale."
Ms. Brege, prior to joining Nodality, held several senior-level
positions at Onyx Pharmaceuticals, Inc., including executive vice
president and chief operating officer. While at Onyx, she led
multiple functions, including commercialization, strategic
planning, corporate development, and medical, scientific and
government affairs. Before joining Onyx, Ms. Brege was a general
partner at Red Rock Capital Management, a venture capital firm
specializing in early-stage financing for technology companies.
Prior to Red Rock, she was the senior vice president and chief
financial officer at COR Therapeutics. Earlier in her career, Ms.
Brege served as vice president and chief financial officer at
Flextronics and vice president and treasurer of The Cooper
Companies. In addition to Portola, Ms. Brege currently sits on the
boards of directors of Acadia Pharmaceuticals, Inc., Aratana
Therapeutics, Inc., Pacira Pharmaceuticals, Inc., and Dynavax
Technologies Corporation. Ms. Brege earned a B.A. from Ohio
University (Honors Tutorial College) and an M.B.A. from the
University of Chicago.
Dr. Fenton, prior to founding Fenton and Associates, served as
executive vice president of operations at Amgen, where he was
responsible for worldwide operations, manufacturing, process
development and quality. Dr. Fenton joined Amgen in 1982 and held
numerous executive leadership roles in operations and sales and
marketing. In addition to Portola, he serves on the boards of
directors of Kythera Biopharmaceuticals, Inc., Hospira, Inc.,
Dendreon Corporation, Nora Therapeutics and XenoPort, Inc. He also
serves on the board of trustees of the Keck Graduate Institute. Dr.
Fenton was previously a director of the Genzyme Corporation,
Genelux Corporation and Amira Pharmaceuticals. He received a B.S.
in Biology from Manhattan College and a Ph.D. in Microbiology from
Rutgers University.
Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. Portola's partnered program is focused on developing
selective Syk inhibitors for inflammatory conditions.
Betrixaban
Portola's wholly-owned, oral, once-daily Factor Xa inhibitor
betrixaban is being evaluated in the only biomarker-based Phase 3
study for hospital-to-home prophylaxis of venous thromboembolism
(VTE) in acute medically ill patients. Betrixaban's distinct
properties may have the potential to allow the agent to demonstrate
efficacy without the significant increase in the rate of major
bleeding that was seen in this patient population with other Factor
Xa inhibitors. If approved, betrixaban could be the first
anticoagulant for both hospital and post-discharge VTE prophylaxis
and the standard of care in this large market of more than 20
million patients in the G7 countries alone.
Andexanet Alfa
Andexanet alfa, a recombinant modified human Factor Xa molecule,
has the potential to be a first-in-class antidote to reverse the
effects of Factor Xa inhibitors in patients who suffer a major
bleeding episode or who require emergency surgery. Andexanet alfa
has been designated as a breakthrough therapy by the U.S. Food and
Drug Administration (FDA). Portola has entered into Phase 3
clinical collaboration agreements with all of the manufacturers of
direct Factor Xa inhibitors – Bristol-Myers Squibb and Pfizer
(Eliquis [apixaban]), Bayer HealthCare and Janssen Pharmaceuticals
(XARELTO® [rivaroxaban]), and Daiichi Sankyo (edoxaban) – while
retaining all commercial rights to andexanet alfa. The Company is
currently evaluating andexanet alfa in the Phase 3 ANNEXA™
(Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of
fXA Inhibitors) registration studies and in a Phase 4 study to
support FDA approval under an Accelerated Approval pathway.
Cerdulatinib
Portola's product candidate in the area of hematologic cancer,
cerdulatinib, is an orally available molecule that uniquely
inhibits two validated tumor proliferation pathways – spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
evaluated in a Phase 1/2a proof-of-concept study in patients with B
cell leukemias or lymphomas with a focus on genetically-defined
subtypes, as well as in patients who have failed therapy due to
relapse or acquired mutations.
For more information, visit www.portola.com and follow the
Company on Twitter @Portola_Pharma.
Forward-looking statement
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
the likelihood of clinical, regulatory and commercial success of
Portola's product candidates and the projected indications for our
project candidates. Risks that contribute to the uncertain nature
of the forward-looking statements include: the accuracy of
Portola's estimates regarding its ability to complete its clinical
trials; the success of Portola's clinical trials and the
demonstrated efficacy of Portola's product candidates thereunder;
the accuracy of Portola's estimates regarding its expenses and
capital requirements; regulatory developments in the United States
and foreign countries; Portola's ability to obtain and maintain
intellectual property protection for its product candidates; and
the loss of key scientific or management personnel. These and other
risks and uncertainties are described more fully in Portola's most
recent filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K and most recent Quarterly
Report on Form 10-Q for the third quarter of 2014, which was filed
on November 4, 2014. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Portola undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
CONTACT: Media: Joey Fleury, BrewLife, jfleury@brewlife.com, 415.946.1090
Investors: Alexandra Santos, Portola Pharmaceuticals, ir@portola.com, 650.246.7239
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024